Topical Testosterone gel in development to treat Hypoactive Sexual Desire Disorder

LibiGel is a testosterone gel developed by BioSante Pharmaceuticals, Inc.  This topical product is in development for the treatment of female sexual dysfunction, specifically, hypoactive sexual desire disorder (HSDD) in menopausal women.  The study is in the Phase III safety study and still needs FDA approval.  Read more at the link below:

http://www.marketwatch.com/story/biosante-pharmaceuticals-reports-positive-libigelr-safety-data-review-for-phase-iii-program-2012-02-09

Please join Boulder Sex Therapy’s mailing list if you’d like further information on this subject.